Immune Report CardSM is a first-in-kind comprehensive immune profiling test designed to inform oncologists regarding checkpoint inhibitor (CPI) treatment decisions.

This 5-test mode assay synthesizes and reports results for all FDA approved CPI companion diagnostics (PD-L1 immunohistochemistry and microsatellite instability) and widely published biomarkers, such as mutational burden and PD-L1/2 copy number variation.

In addition, Immune Report CardSM uses next generation sequencing RNA-seq to quantify messenger RNA (mRNA) levels of 54 essential genes in the immune response cycle relative to a proprietary reference population.

immune report card logoComprehensive Immune Profiling

Express Hope

for ~50% of Patients with Negative Results by Standard Markers

Source: Reprinted from Immunity, Volume 39, Chen, Daniel S. et al., Oncology Meets Immunology: The Cancer-Immunity Cycle, 1-10, Copyright 2013, with permission from Elsevier. http://dx.doi.org/10.1016/j.immuni.2013.07.012

Created in collaboration with an NCI-Designated Comprehensive Cancer Center using tissue-sparing techniques and backed by a significant reference population of treated patients.